Despite international sanctions, Iran has developed a robust domestic pharmaceutical sector, producing 97% of its medicines locally. The industry has grown from 35 foreign-affiliated firms to over 200 Iranian companies, with exports reaching $150 million in 2024.
Iran's Pharmaceutical Industry Thrives Amid Sanctions
Iran's pharmaceutical industry has thrived despite international sanctions, with 97% of medicines produced domestically and the number of local companies increasing significantly. This growth reflects a shift from foreign dependency to self-sufficiency in healthcare. The industry is projected to export $150 million worth of products in 2024.
👥 Key Players
📰 What Happened
Iran's pharmaceutical industry has significantly expanded, now producing 97% of its medicines domestically and increasing the number of local companies to over 200. This growth is a direct response to international sanctions that have limited foreign involvement.
- Iran's pharmaceutical exports are projected to reach $150 million in 2024.
- The number of foreign-affiliated firms in Iran's pharmaceutical sector has decreased from 35 to over 200 local companies.
💡 Why It Matters
📚 Background
Iran has faced extensive international sanctions that have impacted its economy, prompting a push for domestic production across various sectors, including healthcare.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%